<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699010</url>
  </required_header>
  <id_info>
    <org_study_id>AP-ADF-111</org_study_id>
    <nct_id>NCT00699010</nct_id>
  </id_info>
  <brief_title>Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse</brief_title>
  <official_title>A Phase II, Single-Center, Randomized, Double-Blind Assessment of the Abuse Liability of Acurox (Oxycodone HCl and Niacin) Tablets in Subjects With a History of Opioid Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acura Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acura Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is: (1) to assess the effect of oxycodone HCl on niacin-induced
      dysphoric effects when oxycodone HCl is administered in combination with niacin in subjects
      with a history of opioid abuse; (2) to assess the abuse liability of 4 times the usual
      recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40
      mg alone in subjects with a history of opioid abuse.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the Drug Rating Questionnaire-Subject (DRQS), and the Addiction Research Center Inventory (ARCI)</measure>
    <time_frame>Days 1, 3, 5, 7, and 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the DRQS, the ARCI, the Street Value Assessment Questionnaire (SVAQ), and the Treatment Enjoyment Assessment Questionnaire (TEAQ)</measure>
    <time_frame>Day 1, 3, 5, 7, 8, 9, and 10</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Opioid Abuse</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin</intervention_name>
    <description>Niacin 240 mg every 48 hours</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone HCL plus Niacin</intervention_name>
    <description>Oxycodone HCL 40 mg plus Niacin 240 mg every 48 hours</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo every 48 hours</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone HCL plus Niacin</intervention_name>
    <description>Oxycodone HCl 40 mg plus Niacin 240 mg every 48 hours</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone HCl</intervention_name>
    <description>Oxycodone HCl 40 mg every 48 hours</description>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female between 18 and 55 years of age

          -  Subject meets DSM-IV Criteria for the Diagnosis of Opioid Substance Abuse and subject
             is unlikely to experience an idiosyncratic reaction or respiratory depression after
             ingesting 40 mg of oxycodone

          -  Body weight is not more than 20% above or below ideal body weight

          -  Subject agrees to abstain from any Rx or OTC drugs (except as authorized by the
             Investigator) or alcohol

          -  Subject is in generally good health

          -  Subject is reliable, willing, cooperative, able to communicate effectively, and has a
             minimum of a 6th grade reading level

          -  Subject has an acceptable score on the MMSE for cognitive impairment

          -  For women of child-bearing potential: woman is not pregnant and not nursing, and is
             practicing an acceptable method of birth control

        Exclusion Criteria:

          -  Subject has a disease that may endanger the subject or the validity of the data

          -  Subject is currently physically dependent on opiates or alcohol

          -  Subject was exposed to any investigational drug within 30 days prior to the inpatient
             phase

          -  Subject has a history of hypersensitivity to any drug, or a known allergy to any
             component of the study drug formulation

          -  Subject has a positive urine drug screen for a non-opiate drug

          -  Subject has a predisposing condition that may place the subject at risk for receiving
             niacin or oxycodone, or confound the study analyses

          -  Subject ingested niacin at doses higher than SDI within 14 days prior to the inpatient
             phase

          -  Subject has an abnormal bleeding tendency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald R Jasinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>October 22, 2008</last_update_submitted>
  <last_update_submitted_qc>October 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Donald R. Jasinski, MD</name_title>
    <organization>Johns Hopkins Medical Center</organization>
  </responsible_party>
  <keyword>Abuse Liability</keyword>
  <keyword>Abuse Prevention</keyword>
  <keyword>Abuse Resistance</keyword>
  <keyword>Abuse Deterrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

